BACKGROUND. The KRAS proto-oncogene is among the most frequently mutated genes in cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric inhibitors that covalently bind to KRAS G12C mutations have been approved for use in lung adenocarcinomas. Although responses are observed, they are often short-lived, thus making in-depth characterization of the mechanisms of resistance of paramount importance.

中文翻译：

---

对 KRAS G12C 抑制的临床耐药的快速异质机制

背景。KRAS原癌基因是癌症中最常发生突变的基因之一，但 40 年来它仍然是一个难以捉摸的治疗靶点。最近，与 KRAS G12C 突变共价结合的变构抑制剂已被批准用于肺腺癌。尽管可以观察到反应，但它们通常是短暂的，因此对耐药机制的深入表征至关重要。